Drug Discovery

The biochemical landscape of the human body has long been viewed as a battlefield where antioxidants act as the primary defense against the cellular wear and tear that leads to chronic disease. For generations, glutathione has occupied the throne as the "master antioxidant," an essential molecule

Ivan Kairatov is a leading biopharma expert with a profound background in molecular oncology and therapeutic innovation. His extensive research in drug development has centered on the complex interplay between tumor biology and the microenvironment, particularly how cellular communication drives

For decades, the fundamental understanding of the human immune system relied on a strict division of labor where specific molecules directed the activities of specialized cellular defenders against pathogens and tumors. This biological framework, often referred to as the MHC dichotomy, suggested

The high-stakes environment of modern drug discovery often feels like navigating a vast, multidimensional maze where a single structural misstep can derail years of intensive laboratory research. Pharmaceutical scientists frequently grapple with the immense difficulty of predicting how a

The long-standing struggle against small cell neuroendocrine cancers has finally reached a pivotal turning point through the strategic exploitation of genetic dependencies. For over fifty years, patients diagnosed with these aggressive malignancies in the lungs, prostate, or ovaries faced a grim

Ivan Kairatov is a leading biopharma expert with a deep understanding of how generative artificial intelligence is reshaping the landscape of drug development. With extensive experience in research and development, he has been at the forefront of integrating computational biology with traditional